Outcome of Transplantation for Myelofibrosis
| العنوان: | Outcome of Transplantation for Myelofibrosis |
|---|---|
| المؤلفون: | Kathleen A. Sobocinski, Theresa Hahn, Richard T. Maziarz, Brian J. Bolwell, William J. Hogan, Asad Bashey, Vikas Gupta, Vivek Roy, Smriti Shrestha, Steven M. Devine, Sergio Giralt, Mei-Jie Zhang, Mukta Arora, Mark R. Litzow, Harry C. Schouten, Gary J. Schiller, David I. Marks, Robert Peter Gale, Mary M. Horowitz, Philip L. McCarthy, Kröger N, Francisco Cervantes, Karen K. Ballen, Peter H. Wiernik |
| المساهمون: | Interne Geneeskunde, RS: GROW - School for Oncology and Reproduction |
| المصدر: | Biology of Blood and Marrow Transplantation, 16(3), 358-367. Elsevier Science |
| بيانات النشر: | Elsevier Science, 2010. |
| سنة النشر: | 2010 |
| مصطلحات موضوعية: | Graft Rejection, Male, Transplantation Conditioning, medicine.medical_treatment, Graft vs Host Disease, Myelofibrosis, Kaplan-Meier Estimate, Hematopoietic stem cell transplantation, Postoperative Complications, 0302 clinical medicine, Recurrence, Risk Factors, Graft Survival, Hematopoietic Stem Cell Transplantation, Hematology, Middle Aged, 3. Good health, Treatment Outcome, surgical procedures, operative, Histocompatibility, 030220 oncology & carcinogenesis, Female, Adult, medicine.medical_specialty, Allogeneic transplantation, Adolescent, Splenectomy, Disease-Free Survival, Article, Young Adult, 03 medical and health sciences, Internal medicine, medicine, Humans, Transplantation, Homologous, Karnofsky Performance Status, Aged, Retrospective Studies, Transplantation, business.industry, Siblings, Retrospective cohort study, medicine.disease, Surgery, Primary Myelofibrosis, Splenomegaly, business, 030215 immunology |
| الوصف: | Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients. Biol Blood Marrow Transplant 16: 358-367 (2010) |
| اللغة: | English |
| تدمد: | 1523-6536 1083-8791 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9571d7e9e9430d3a18394438da5d8243Test https://cris.maastrichtuniversity.nl/en/publications/a49a44b9-c80b-4518-8f78-fa8c61c1f560Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....9571d7e9e9430d3a18394438da5d8243 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15236536 10838791 |
|---|